Matches in SemOpenAlex for { <https://semopenalex.org/work/W4353015300> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4353015300 endingPage "264" @default.
- W4353015300 startingPage "259" @default.
- W4353015300 abstract "Objective: To investigate the clinical characteristics of abnormal liver function in patients with advanced esophageal squamous carcinoma treated with programmed death-1 (PD-1) antibody SHR-1210 alone or in combination with apatinib and chemotherapy. Methods: Clinical data of 73 patients with esophageal squamous carcinoma from 2 prospective clinical studies conducted at the Cancer Hospital Chinese Academy of Medical Sciences from May 11, 2016, to November 19, 2019, were analyzed, and logistic regression analysis was used for the analysis of influencing factors. Results: Of the 73 patients, 35 had abnormal liver function. 13 of the 43 patients treated with PD-1 antibody monotherapy (PD-1 monotherapy group) had abnormal liver function, and the median time to first abnormal liver function was 55 days. Of the 30 patients treated with PD-1 antibody in combination with apatinib and chemotherapy (PD-1 combination group), 22 had abnormal liver function, and the median time to first abnormal liver function was 41 days. Of the 35 patients with abnormal liver function, 2 had clinical symptoms, including malaise and loss of appetite, and 1 had jaundice. 28 of the 35 patients with abnormal liver function returned to normal and 7 improved to grade 1, and none of the patients had serious life-threatening or fatal liver function abnormalities. Combination therapy was a risk factor for patients to develop abnormal liver function (P=0.007). Conclusions: Most of the liver function abnormalities that occur during treatment with PD-1 antibody SHR-1210 alone or in combination with apatinib and chemotherapy are mild, and liver function can return to normal or improve with symptomatic treatment. For patients who receive PD-1 antibody in combination with targeted therapy and chemotherapy and have a history of long-term previous smoking, alcohol consumption and hepatitis B virus infection, liver function should be monitored and actively managed in a timely manner.目的： 探讨经程序性死亡蛋白1(PD-1)抗体卡瑞利珠单抗单药或联合阿帕替尼和化疗治疗晚期食管鳞状细胞癌(鳞癌)患者肝功能异常的临床特征。 方法： 分析2016年5月11日至2019年11月19日于中国医学科学院肿瘤医院开展的2项前瞻性临床研究中73例食管鳞癌患者的临床资料，影响因素分析采用logistic回归分析。 结果： 73例患者中，出现肝功能异常35例。PD-1抗体单药治疗的43例患者中，肝功能异常13例，首次发生肝功能异常的中位时间为55 d。PD-1抗体联合阿帕替尼和化疗治疗的30例患者中，肝功能异常22例，首次发生肝功能异常的中位时间为41 d。35例肝功能异常患者中，伴有临床症状者2例，临床症状为乏力、食欲减低，其中1例伴有黄疸。35例肝功能异常患者中，28例患者肝功能恢复正常，7例患者肝功能好转至1级，无一例患者因肝功能异常严重危及生命或死亡。联合治疗是患者出现肝功能异常的危险因素(P＝0.007)。 结论： PD-1抗体卡瑞利珠单抗单药或联合阿帕替尼和化疗治疗过程中，大部分患者发生肝功能异常的程度较轻，经对症治疗后肝功能可恢复正常或好转。对于接受PD-1抗体联合靶向治疗和化疗、既往有长期吸烟史、饮酒史及乙肝病毒感染史的患者，应及时监测肝功能并积极处理。." @default.
- W4353015300 created "2023-03-23" @default.
- W4353015300 creator A5005938884 @default.
- W4353015300 creator A5006112568 @default.
- W4353015300 creator A5017698850 @default.
- W4353015300 creator A5024072785 @default.
- W4353015300 creator A5037955408 @default.
- W4353015300 creator A5039473680 @default.
- W4353015300 creator A5058840878 @default.
- W4353015300 creator A5061431519 @default.
- W4353015300 creator A5066284020 @default.
- W4353015300 date "2023-03-23" @default.
- W4353015300 modified "2023-09-28" @default.
- W4353015300 title "[Clinical analysis of liver dysfunction induced by SHR-1210 alone or combined with apatinib and chemotherapy in patients with advanced esophageal squamous cell carcinoma]." @default.
- W4353015300 doi "https://doi.org/10.3760/cma.j.cn112152-20200927-00858" @default.
- W4353015300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36944547" @default.
- W4353015300 hasPublicationYear "2023" @default.
- W4353015300 type Work @default.
- W4353015300 citedByCount "0" @default.
- W4353015300 crossrefType "journal-article" @default.
- W4353015300 hasAuthorship W4353015300A5005938884 @default.
- W4353015300 hasAuthorship W4353015300A5006112568 @default.
- W4353015300 hasAuthorship W4353015300A5017698850 @default.
- W4353015300 hasAuthorship W4353015300A5024072785 @default.
- W4353015300 hasAuthorship W4353015300A5037955408 @default.
- W4353015300 hasAuthorship W4353015300A5039473680 @default.
- W4353015300 hasAuthorship W4353015300A5058840878 @default.
- W4353015300 hasAuthorship W4353015300A5061431519 @default.
- W4353015300 hasAuthorship W4353015300A5066284020 @default.
- W4353015300 hasConcept C121608353 @default.
- W4353015300 hasConcept C126322002 @default.
- W4353015300 hasConcept C2776694085 @default.
- W4353015300 hasConcept C2776999253 @default.
- W4353015300 hasConcept C2777546739 @default.
- W4353015300 hasConcept C2778456037 @default.
- W4353015300 hasConcept C2780668389 @default.
- W4353015300 hasConcept C2992208098 @default.
- W4353015300 hasConcept C512861765 @default.
- W4353015300 hasConcept C71924100 @default.
- W4353015300 hasConcept C90924648 @default.
- W4353015300 hasConceptScore W4353015300C121608353 @default.
- W4353015300 hasConceptScore W4353015300C126322002 @default.
- W4353015300 hasConceptScore W4353015300C2776694085 @default.
- W4353015300 hasConceptScore W4353015300C2776999253 @default.
- W4353015300 hasConceptScore W4353015300C2777546739 @default.
- W4353015300 hasConceptScore W4353015300C2778456037 @default.
- W4353015300 hasConceptScore W4353015300C2780668389 @default.
- W4353015300 hasConceptScore W4353015300C2992208098 @default.
- W4353015300 hasConceptScore W4353015300C512861765 @default.
- W4353015300 hasConceptScore W4353015300C71924100 @default.
- W4353015300 hasConceptScore W4353015300C90924648 @default.
- W4353015300 hasIssue "3" @default.
- W4353015300 hasLocation W43530153001 @default.
- W4353015300 hasOpenAccess W4353015300 @default.
- W4353015300 hasPrimaryLocation W43530153001 @default.
- W4353015300 hasRelatedWork W1438385086 @default.
- W4353015300 hasRelatedWork W165286714 @default.
- W4353015300 hasRelatedWork W1975819389 @default.
- W4353015300 hasRelatedWork W2000057783 @default.
- W4353015300 hasRelatedWork W2350383809 @default.
- W4353015300 hasRelatedWork W2354834060 @default.
- W4353015300 hasRelatedWork W2379810239 @default.
- W4353015300 hasRelatedWork W2391710804 @default.
- W4353015300 hasRelatedWork W2409623545 @default.
- W4353015300 hasRelatedWork W3145239532 @default.
- W4353015300 hasVolume "45" @default.
- W4353015300 isParatext "false" @default.
- W4353015300 isRetracted "false" @default.
- W4353015300 workType "article" @default.